Cancer
Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Published in Cancer Weekly, May 5th, 2009
Dendreon Corporation (NASDAQ: DNDN) announced that the Company has enrolled the first patient in a Phase 1 clinical trial of D3263 in patients with advanced cancer. D3263 is Dendreon's lead small molecule drug candidate designed to target TRPM8 (a transmembrane cation channel protein) in cancer cells and induce cell death. The trial is an open-label, dose-escalation study evaluating the safety and pharmacokinetics of orally-administered D3263 in patients with solid tumors that are refractory to standard therapies.
The Phase 1 trial will enroll three to six patients per cohort during the dose escalation phase of the study. An expansion cohort may be enrolled following...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-05-05)
More Articles from Cancer Weekly
- Brain Cancer
Study results from Brain Tumor Center provide new insights into brain cancer - Cancer Gene Therapy
Research conducted at University of Marburg, Medical Department has updated our knowledge about cancer gene therapy - Cancer Gene Therapy
Research reports on cancer gene therapy from I. Gentschev and colleagues provide new insights - Cancer Vaccines
Newly published study shows that re-treatment with PegasysŪ (peginterferon alfa-2a) provides hepatitis C patients with a second chance for a cure - Cancer Vaccines
Reports from Baylor College of Medicine, College of Medicine describe recent advances in cancer vaccines - Cancer Vaccines
Researchers from University of Georgia report details of new studies and findings in the area of cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
